Sugi Predict

Sugi Predict / Compounds / SCHEMBL1789519

SCHEMBL1789519

SCHEMBL1789519

CN(C)C(=O)c1ccccc1B(O)O

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.58
▸ KMT2A Q03164 4/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ KEAP1 Q14145 1/20 0.51
▸ ALDH1A1 P00352 5/20 0.41
▸ MAPT P10636 2/20 0.41
▸ TP53 P04637 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ POLB P06746 1/20 0.38
▸ CXCR2 P25025 1/20 0.38
▸ ENPP2 Q13822 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29956764 1.00 MEN1 (0.58) MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1
SCHEMBL30689988 0.85 KMT2A (0.47) MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1
SCHEMBL3786429 0.82 MEN1 (0.44) MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1
SCHEMBL188296 0.82 MEN1 (0.65) MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1
SCHEMBL29957894 0.81 MEN1 (0.43) MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1
SCHEMBL31419627 0.81 MEN1 (0.43) MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1
SCHEMBL2761568 0.81 ENPP2 (0.41) MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1
SCHEMBL3954840 0.80 KMT2A (0.39) MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1
SCHEMBL3790283 0.79 MEN1 (0.48) MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1
SCHEMBL1477106 0.79 P2RX4 (0.47) MEN1KMT2ASMN1; SMN2KEAP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115627118-B Ball valve casting and processing technology thereof 温州市海格阀门有限公司 2024-03-19 — — CN claimed
CN-115627118-A Ball valve casting and machining process thereof 温州市海格阀门有限公司 2023-01-20 — — CN claimed
CN-115627118-B Ball valve casting and processing technology thereof 温州市海格阀门有限公司 2024-03-19 — — CN disclosed
CN-115627118-B Ball valve casting and processing technology thereof 温州市海格阀门有限公司 2024-03-19 — — CN disclosed
WO-2024006726-A2 COMPOUNDS AS INHIBITORS OF AXL ARCUS BIOSCIENCES, INC. (US) 2024-01-04 — — WO disclosed
US-20230416277-A1 COMPOUNDS AS INHIBITORS OF AXL ARCUS BIOSCIENCES, INC. 2023-12-28 — — US disclosed
US-20230181462-A1 Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-06-15 — — US disclosed
CN-115812085-A Dynamic covalent hydrogels, precursors thereof and uses thereof 国家科学研究中心 2023-03-17 — — CN disclosed
CN-115627118-A Ball valve casting and machining process thereof 温州市海格阀门有限公司 2023-01-20 — — CN disclosed
CN-115627118-A Ball valve casting and machining process thereof 温州市海格阀门有限公司 2023-01-20 — — CN disclosed
EP-4118136-A1 DYNAMIC COVALENT HYDROGELS, PRECURSORS THEREOF AND USES THEREOF Centre National de la Recherche Scientifique (CNRS) (FR) 2023-01-18 — — EP disclosed
EP-2124913-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS Novartis AG (CH) 2009-12-02 — — EP disclosed
WO-2009082346-A1 NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 ASTRAZENECA AB (SE) 2009-07-02 — — WO disclosed
EP-1979353-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2008-10-15 — — EP disclosed
WO-2008077597-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS NOVARTIS AG (CH) 2008-07-03 — — WO disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 — — EP disclosed
WO-2007084667-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI PHARMACEUTICAL, INC. (US) 2007-07-26 — — WO disclosed
EP-1768966-A1 COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS Infinity Pharmaceuticals, Inc. (US) 2007-04-04 — — EP disclosed
WO-2006009869-A1 COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS INFINITY PHARMACEUTICALS, INC. (US) 2006-01-26 — — WO disclosed
WO-2005087765-A1 LIGANDS OF FOLLICLE STIMULATING HORMONE RECEPTOR AND METHODS OF USE THEREOF ARENA PHARMACEUTICALS, INC. (US) 2005-09-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181462-A1 Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof CDC37, ILK, PTMS MEN1 4666/4885KMT2A 2860/4885SMN1; SMN2 4769/4885
US-20230416277-A1 COMPOUNDS AS INHIBITORS OF AXL AXL, FLT3, BTK MEN1 417/4885KMT2A 1989/4885SMN1; SMN2 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.